FRONTEO partners with Springer Nature to develop new services for interdisciplinary scientific paper analysis

Home » corporate » News » 2022 » FRONTEO partners with Springer Nature to develop new services for interdisciplinary scientific paper analysis
2022.12.20 Press release

--To the press -

FRONTEO partners with Springer Nature to develop new services for interdisciplinary scientific paper analysis

Covering more than 600 titles from Springer and Nature journals

FRONTEO Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Growth)

 FRONTEO, Inc. (HQ: Minato-ku, Tokyo; CEO: Masahiro Morimoto) announces that it has partnered with Springer Nature (HQ: Berlin, Germany; CEO: Frank Vrancken Peeters) to develop new services by utilizing article information.

 Springer Nature is a global academic publishing company headquartered in Germany with offices globally. The company publishes many excellent academic journals and books, including Nature, the most representative scientific journal, and also provides databases and research services. In this partnership FRONTEO will develop a new biological science information analysis platform, by combining the strengths of Springer Nature’s article data published in more than 600 influential journals and FRONTEO's natural language analysis AI technologies.

FRONTEO released Amanogawa in July XNUMX as an AI system for researching and analyzing papers, and it is currently being deployed by universities, pharmaceutical companies, medical institutions, and other research organizations. The system uses as its data source information on articles in PubMed (https://pubmed.ncbi.nlm.nih.gov/), the biomedical article database operated by the National Center for Biomedical Information of the National Library of Medicine.

 On the other hand, since Springer Nature’s article data are not only the abstracts but also the full text, it is anticipated that having AI learn from them will lead to more advanced analysis and information extraction. Furthermore, those articles cover a wide range of fields such as biomedicine, science, environment, materials science, psychology, engineering, nutrition, etc. By analyzing these data with AI, it is expected to enable comprehensive analysis including papers in various fields that have not been connected, and to lead to the sharing of knowledge across academic boundaries and the creation of new innovation.

Prathik Roy, Director, Data Solutions and Strategy, Springer Nature said: 
“Springer Nature has been in the forefront of leading research in the space of life sciences and pharma. We look forward to this new collaboration with FRONTEO to provide researchers and data scientists with great insight into research conducted in the life sciences which combines the power of Springer Nature’s rich dataset and FRONTEO’s state of the art AI solution.”

 FRONTEO will continue to contribute to the development of innovative studies by providing solutions that utilize in-house developed AI, which has strengths in natural language processing.

 The impact of this matter alone on the business results for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.


■ About Amanogawa
URL: URL: https://lifescience.fronteo.com/aidiscovery/amanogawa/
Amanogawa is an article-seeking AI system with FRONTEO's unique AI engines Concept Encoder (conceptencoder™). When a researcher enters a sentence such as a word or hypothesis of interest, Concept Encoder detects articles related to the input content in a moment from a large number of articles on PubMed. Search results are plotted in a map based on the degree of similarity between articles, and the relevance can be confirmed at a glance, and a visual article search that has not been done before can be performed by dragging the detected article information on the map to narrow down the search. In addition, search results are listed in descending order of relevance, and abstracts are listed, which greatly streamlines the search for papers. This will assist people in discovering events and new drug targets from difficult-to-notice perspectives. Patent No. 6976537

■ About FRONTEO URL:https://www.fronteo.com/
FRONTEO is a data analysis company that uses the in-house developed AI engines KIBIT and Concept Encoder, Looca Cross specialized in natural language processing to extract meaningful and significant information from a large amount of textual data and support companies' business. Since its inception in August 2003, we have been working globally with Japan, the United States, Korea, and Taiwan, mainly in the Legaltech business, such as e-discovery (electronic evidence disclosure) and digital forensic surveys, which support company international lawsuits. Based on AI technology developed in this project, we have expanded our business fields to life science, business intelligence, and economic security since 8, and have used AI to transform textual data into knowledge, thus contributing to the resolution of various companies' issues, including support for drug discovery, support for dementia diagnostics, and support for financial, human resources, and business. Listed on TSE Mothers (currently TSE Growth) on June 2014, 2007. In January 6, the company obtained a license to manufacture and sell Class I medical devices (license number: 26B2021X1), and in September of the same year, the company submitted a notification to sell controlled medical devices (notification number: 13MinatoMiSeikikiDai1). Capital: ¥10350 (as of March 9, 3).

※FRONTEO, Amanogawa, KIBIT, conceptencoder, Looca Cross are registered trademarks of FRONTEO.

 

Inquiry by the media
PR Department, FRONTEO, Inc.
Email: pr_contact@fronteo.com

Inquiries concerning Life Science AI Business
Life Science AI Business Department, FRONTEO, Inc.
https://lifescience.fronteo.com/contact